BlackRock’s Allena Pharmaceuticals ALNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-228,215
| Closed | -$44K | – | 6006 |
|
|
2022
Q2 | $44K | Sell |
228,215
-30,705
| -12% | -$4.76K | ﹤0.01% | 5438 |
|
|
2022
Q1 | $61K | Sell |
258,920
-5,319
| -2% | -$2.2K | ﹤0.01% | 5387 |
|
|
2021
Q4 | $156K | Buy |
264,239
+8,819
| +3% | +$6.9K | ﹤0.01% | 5157 |
|
|
2021
Q3 | $230K | Buy |
255,420
+5,814
| +2% | +$5.69K | ﹤0.01% | 4949 |
|
|
2021
Q2 | $325K | Buy |
249,606
+59,804
| +32% | +$72.4K | ﹤0.01% | 4789 |
|
|
2021
Q1 | $264K | Buy |
189,802
+25,746
| +16% | +$42.9K | ﹤0.01% | 4694 |
|
|
2020
Q4 | $210K | Buy |
164,056
+28,858
| +21% | +$40.2K | ﹤0.01% | 4476 |
|
|
2020
Q3 | $200K | Buy |
135,198
+1,656
| +1% | +$2.33K | ﹤0.01% | 4412 |
|
|
2020
Q2 | $211K | Buy |
133,542
+12,986
| +11% | +$21.8K | ﹤0.01% | 4365 |
|
|
2020
Q1 | $116K | Sell |
120,556
-7,698
| -6% | -$15.4K | ﹤0.01% | 4328 |
|
|
2019
Q4 | $350K | Sell |
128,254
-25,762
| -17% | -$84.6K | ﹤0.01% | 4226 |
|
|
2019
Q3 | $606K | Buy |
154,016
+38,360
| +33% | +$165K | ﹤0.01% | 4120 |
|
|
2019
Q2 | $471K | Sell |
115,656
-492,237
| -81% | -$2.69M | ﹤0.01% | 4204 |
|
|
2019
Q1 | $4.27M | Buy |
607,893
+25,922
| +4% | +$188K | ﹤0.01% | 3464 |
|
|
2018
Q4 | $3.17M | Buy |
581,971
+4,528
| +0.8% | +$39K | ﹤0.01% | 3532 |
|
|
2018
Q3 | $6.2M | Buy |
577,443
+9,736
| +2% | +$107K | ﹤0.01% | 3431 |
|
|
2018
Q2 | $7.4M | Buy |
567,707
+336,053
| +145% | +$4.85M | ﹤0.01% | 3372 |
|
|
2018
Q1 | $2.55M | Buy |
231,654
+4,879
| +2% | +$40.8K | ﹤0.01% | 3616 |
|
|
2017
Q4 | $2.28M | Buy |
+226,775
| New | +$2.79M | ﹤0.01% | 3659 |
|
Other funds holding ALNA
BlackRock's ALNA Position: Q3 2022 in Review
BlackRock sold out of Allena Pharmaceuticals (ALNA) in Q3 2022, closing a stake of 228,215 shares — an estimated $44K sold.
BlackRock first reported a position in ALNA in Q4 2017 and held it in 19 quarters. The position peaked at $7.4M in Q2 2018. 2 funds tracked by Wall St. Rank hold ALNA as of Q3 2022.
- BlackRock reported no remaining Allena Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
- BlackRock sold 228,215 Allena Pharmaceuticals shares in Q3 2022, an estimated $44K.
- BlackRock first reported a position in Allena Pharmaceuticals in Q4 2017 and held it in 19 quarters.
- BlackRock's Allena Pharmaceuticals position peaked at $7.4M in Q2 2018.
- 2 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q3 2022.
Based on BlackRock's 13F filing for Q3 2022, filed 14 Nov 2022.